theMednetRegister

Hematologic Malignancies

ASH 2025   

Questions discussed in this category

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?
Aza/ven patients had better EFS/QoL with a greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is...
1 Answer available
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
Should all CLL patients be candidates for fixed-duration treatments?
1 Answer available


Papers discussed in this category

Lancet (London, England), 2020 Apr 18
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
The New England journal of medicine, 2025 Dec 06
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Related Topics in Hematologic Malignancies

Copyright © 2025 theMednet
All Rights Reserved.